Annexon, Inc. (NASDAQ:ANNX – Get Free Report) has been given a consensus rating of “Hold” by the ten ratings firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $15.14.
A number of research firms have recently commented on ANNX. Citigroup assumed coverage on shares of Annexon in a research report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Annexon in a research note on Monday, July 20th. Citizens Jmp upgraded shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Monday, July 13th.
View Our Latest Stock Analysis on Annexon
Hedge Funds Weigh In On Annexon
Annexon Stock Performance
ANNX opened at $3.80 on Friday. The company has a market cap of $720.40 million, a PE ratio of -3.28 and a beta of 1.21. The stock has a 50-day moving average of $4.91 and a 200-day moving average of $5.32. Annexon has a 52-week low of $2.54 and a 52-week high of $7.18.
Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). On average, research analysts predict that Annexon will post -1.04 earnings per share for the current year.
About Annexon
Annexon, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for diseases driven by the classical complement pathway, an immune system mechanism that can contribute to inflammation and the destruction of healthy cells. The company’s approach is designed to selectively inhibit complement activity while preserving other potentially beneficial immune functions.
Annexon’s lead programs include ANX005, an investigational monoclonal antibody that targets C1q and is being evaluated in immune-mediated and neuroinflammatory conditions, including Guillain-Barré syndrome.
See Also
- Five stocks we like better than Annexon
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.
